General Information |
| Summary |
This is an open-label, Phase I study of QN-019a (allogeneic CAR-NK cells targeting CD19) as monotherapy in relapsed/refractory B-cell Acute Lymphoblastic Leukemia (B-ALL) and in combination with Rituximab in relapsed/refractory B-cell Lymphoma.
This clinical study is to evaluate the safety, tolerability and preliminary efficacy of QN-019a in patients with relapsed/refractory B-cell lymphoma or B-ALL. Up to 22-36 patients will be enrolled. |
| Description |
This is an open-label, Phase I study of QN-019a (allogeneic CAR-NK cells targeting CD19) as monotherapy in relapsed/refractory B-cell Acute Lymphoblastic Leukemia (B-ALL) and in combination with Rituximab in relapsed/refractory B-cell Lymphoma. |
| Clinical trials phase |
Phase 1 |
| Start date (estimated) |
2021-11-04 |
| End date (estimated) |
2024-12-31 |
| Clinical feature |
| Label |
B-cell acute lymphoblastic leukemia |
| Link |
http://purl.obolibrary.org/obo/DOID_0080638 |
| Description |
An acute lymphocytic leukemia characterized by too many B-cell lymphoblasts (immature white blood cells) in the bone marrow and blood. |
|
Administrative Information |
| NCT number |
NCT05379647 |
| ICTRP weblink |
https://trialsearch.who.int/Trial2.aspx?TrialID=NCT05379647 |
| Other study identifiers |
|
| Source weblink |
https://clinicaltrials.gov/ct2/show/NCT05379647 |
| Sponsors |
Zhejiang University
|
| Collaborators |
|
Cells |
| Which differentiated cell type is used |
| Label |
natural killer cell |
| Link |
http://purl.obolibrary.org/obo/CL_0000623 |
| Description |
A lymphocyte that can spontaneously kill a variety of target cells without prior antigenic activation via germline encoded activation receptors and also regulate immune responses via cytokine release and direct contact with other cells. |
|
Recruitment |
| Recruitment Status |
Recruiting |
| Estimated number of participants |
24 |
| Contact institutions/departments |
|
